At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...
Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
Fintel on MSN1d
Maxim Group Downgrades Gilead Sciences (GILD)Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...
Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...
An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Welcome to Gilead. All the postmortems are really missing the point. The evangelicals did this. This is your open thread for Sunday morning. Feel free to rant, scream or if you have positive things to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback